AB1283 COVID-19 WAS NOT TRIGGER FOR RHEUMATIC DISEASE ACTIVITY AFTER 6 MONTHS FOLLOW-UP: RESULTS FROM REUMACOV BRASIL REGISTER

Background The COVID-19 pandemic has brought uncertainties to rheumatology practice, mainly related the possibility of triggering disease activity after infection in immune mediated rheumatic diseases (IMRD). To date, there are few data literature specifically evaluating this issue. Objectives Evaluate IMRD patients 6 months infection, compared pre status. Methods ReumaCoV Brasil is a longitudinal study performed at 35 centers designed follow-up for clinical or laboratorial diagnosis (cases), comparing with who had not time inclusion (controls). Demographic such as age, sex, comorbidities, characteristics, treatment, evolution and status were collected using Research Eletronic Data Capture (REDCap) database on three consecutive visits (inclusion months). analysis was carried out four highest number study: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS) psoriatic (PsA). In addition specific assessment metrics, we used patient’s global (PGA), ranging from 0 10, all visits, being no 10 intense activity. All conclusions drawn considering significance level 5%. This registered Brazilian Registry Clinical Trials—REBEC, RBR-33YTQC. read signed informed consent form before inclusion. Results Between May 2020 January 2021, 2032 included registry, these, 1322 (721 cases 601 controls), completed follow-up, 550 SLE (42.0%), 497 RA (37.6%) 176 SpA (13.3%) 99 (7.4%) PsA. Most female (82.0%); median age 46.7 (13.8). Disease enrollment, according PGA, similar between controls, except AS, where it higher controls. After follow up time, worsening observed any evaluated case group (Table 1). Despite this, symptoms reported by 23.3%, 24.6%, 25.0% 25.8% SLE, RA, AS PsA respectively, Conclusion IMRD, cohort patients. many noticed symptoms, possibly associated activity, but so-called long COVID syndrome. Table 1. Comparison up, controls INCLUSION AFTER MONTHS Cases Controls p-value 2 (0-4,5) (0-4) 0,810 (0-5) 0,172 3 (1-5) 4 (2-6) 0.001 (1-5,5) 0,731 (1-6) 0,002 3,5 0,044 0,816 0,939 *Median interquatile range; Student t test; CI 95% Acknowledgements researchers, Society Rheumatology National Council Ccientific Technological Development. Disclosure Interests None Declared.